LONDON and PHOENIX, Ariz., June 06, 2023 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, today announced the establishment of a joint clinical collaboration agreement with University Hospitals.
Per the terms of this agreement, University Hospitals will provide tissue samples with clinical outcomes to AccuStem for research purposes. The scope of the agreement covers a multitude of different cancers but will initially focus on breast cancer cases to support further validation of the StemPrintER test. The goal of the initial project is to build on the strong foundation of data for StemPrintER by demonstrating additional clinical utility beyond identifying patients' risk of recurrence. This next step is critical for women with early stage breast cancer because there are many tests to determine the need for chemotherapy but there are no genomic tools to inform decisions earlier in the continuum of care. StemPrintER may be able to shift this paradigm by informing physicians of the most effective approaches to surgical or radiological treatment.
"AccuStem has arrived at an important juncture as we progress toward commercializing StemPrintER," said Wendy Blosser, Chief Executive Officer of AccuStem. "With this collaboration, we intend to expand beyond identifying a patient's prognosis by addressing unanswered clinical questions and supporting surgeons and radiation oncologists with their treatment planning."
AccuStem and its clinical collaborators plan to present the data obtained under this agreement at scientific conferences and to publish the findings in peer-reviewed medical journals. Those activities will help to bolster the foundation of data for StemPrintER and familiarize physicians with its utility and value in clinical decision making with the ultimate goal of improving patient outcomes and quality of life.
"We are excited to work with AccuStem on this clinical project," said Hannah Gilmore, Division Chief, Anatomic Pathology, University Hospitals Cleveland Medical Center and Professor of Pathology, Case Western Reserve University. "I am very interested in the foundation for the StemPrintER test and think that it could have important implications for treatment planning in breast cancer and perhaps many other tumor types."
About AccuStem
AccuStem is a clinical stage diagnostics company dedicated to optimizing outcomes and quality of life for all patients with cancer. We plan to drive innovation in healthcare by offering proprietary molecular testing that addresses unmet clinical needs from cancer screening through treatment and monitoring. By interrogating novel disease pathways, such as tumor "stemness", we believe our tools will help care teams better understand the biology of each patient's cancer, leading to more informed decision making. For more information, please visit .
About University Hospitals / Cleveland, Ohio
Founded in 1866, University Hospitals serves the needs of patients through an integrated network of 21 hospitals (including five joint ventures), more than 50 health centers and outpatient facilities, and over 200 physician offices in 16 counties throughout northern Ohio. The system's flagship quaternary care, academic medical center, University Hospitals Cleveland Medical Center, is affiliated with Case Western Reserve University School of Medicine, Northeast Ohio Medical University, Oxford University, the Technion Israel Institute of Technology and Taiwan University College of Medicine. The main campus also includes the UH Rainbow Babies & Children's Hospital, ranked among the top children's hospitals in the nation; UH MacDonald Women's Hospital, Ohio's only hospital for women; and UH Seidman Cancer Center, part of the NCI-designated Case Comprehensive Cancer Center. UH is home to some of the most prestigious clinical and research programs in the nation, with more than 3,000 active clinical trials and research studies underway. UH Cleveland Medical Center is perennially among the highest performers in national ranking surveys, including "America's Best Hospitals" from U.S. News & World Report. UH is also home to 19 Clinical Care Delivery and Research Institutes. UH is one of the largest employers in Northeast Ohio with more than 30,000 employees.
伦敦和亚利桑那州菲尼克斯,2023年6月6日(GLOBE NEWSWIRE)——致力于改善癌症患者预后的临床阶段诊断公司AccuStem Sciences, Inc.(OTCQB:ACUT)今天宣布与大学医院签订联合临床合作协议。
根据该协议的条款,大学医院将向AccuStem提供具有临床结果的组织样本,用于研究目的。该协议的范围涵盖多种不同的癌症,但最初将侧重于乳腺癌病例,以支持StemPrinter测试的进一步验证。最初项目的目标是在StemPrinter的坚实数据基础上再接再厉,展示除识别患者复发风险之外的其他临床用途。下一步对于患有早期乳腺癌的女性至关重要,因为有许多测试可以确定化疗的必要性,但是没有基因组工具可以在护理的早期阶段为决策提供信息。StemPrinter 可以通过告知医生最有效的外科或放射治疗方法来改变这种模式。
AccuStem首席执行官温迪·布洛瑟说:“随着我们在StemPrinter商业化方面取得进展,AccuStem已经到了一个重要时刻。”“通过此次合作,我们打算通过解决悬而未决的临床问题以及支持外科医生和放射肿瘤学家制定治疗计划,将范围扩大到确定患者的预后之外。”
AccuStem及其临床合作者计划在科学会议上介绍根据该协议获得的数据,并在同行评审的医学期刊上发表研究结果。这些活动将有助于巩固StemPrinter的数据基础,并使医生熟悉其在临床决策中的效用和价值,最终目标是改善患者的预后和生活质量。
克利夫兰大学医院医学中心解剖病理学系主任、凯斯西储大学病理学教授汉娜·吉尔摩说:“我们很高兴能与AccuStem合作开展这个临床项目。”“我对StemPrinter测试的基础非常感兴趣,并认为它可能对乳腺癌乃至许多其他肿瘤类型的治疗计划产生重要影响。”
关于 accuStem
AccuStem 是一家临床阶段诊断公司,致力于优化所有癌症患者的预后和生活质量。我们计划通过提供专有分子测试来推动医疗保健领域的创新,以解决从癌症筛查到治疗和监测等未得到满足的临床需求。通过调查诸如肿瘤 “干性” 之类的新疾病途径,我们相信我们的工具将帮助医疗团队更好地了解每位患者癌症的生物学,从而做出更明智的决策。欲了解更多信息,请访问。
大学医院简介 /俄亥俄州克利夫兰
大学医院成立于 1866 年,通过由 21 家医院(包括五家合资企业)、50 多个医疗中心和门诊设施以及位于俄亥俄州北部 16 个县的 200 多个医生办公室组成的综合网络来满足患者的需求。该系统的旗舰第四纪医疗学术医学中心克利夫兰大学医院医学中心隶属于凯斯西储大学医学院、东北俄亥俄医科大学、牛津大学、以色列理工学院和台湾大学医学院。主校区还包括UH Rainbow Babies & Children's Hospital,该医院位居全美顶级儿童医院之列;UH MacDonald女子医院,这是俄亥俄州唯一一家女性医院;以及UH Seidman癌症中心,它是NCI指定的凯斯综合癌症中心的一部分。UH 是美国一些最负盛名的临床和研究项目的所在地,有 3,000 多项活跃的临床试验和研究正在进行中。在包括《美国新闻与世界报道》中的 “美国最佳医院” 在内的全国排名调查中,UH Cleveland医学中心长期以来一直是表现最好的医院之一。UH 还是 19 个临床护理提供和研究机构的所在地。UH 是俄亥俄州东北部最大的雇主之一,拥有 30,000 多名员工。